NCT00369954撤回2 期
A Phase II Trial of Intravenous Gemcitabine (NSC #613327) and Intraperitoneal Carboplatin (NSC # 241240) in the Treatment of Patients With Platinum-Sensitive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma With Non-Measurable Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Relative risk of progression-free survival
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them in different ways may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects and how well giving gemcitabine together with carboplatin works in treating patients with persistent or recurrent ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer that responded to previous cisplatin or carboplatin.
详细描述
OBJECTIVES:
Primary
- Determine the progression-free survival of patients with persistent or recurrent platinum-sensitive ovarian epithelial, fallopian tube, or primary peritoneal cancer treated with gemcitabine hydrochloride and intraperitoneal carboplatin.
- Evaluate the systemic and regional toxicity of this regimen in these patients.
Secondary
- Determine the overall survival of patients treated with this regimen.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer
- •Persistent or recurrent disease
- •Nonmeasurable disease
- •Platinum-sensitive disease
- •Must have attained a clinically defined complete response after prior platinum- (cisplatin or carboplatin) and taxane-based combination chemotherapy regimen
- •Patients with partial response or disease progression after first-line therapy are not eligible
- •No disease recurrence within 6 months after completion of first-line platinum-taxane therapy
- •Must have undergone laparoscopy or laparotomy for either of the following:
- •Second-look surgery after a complete response to first-line therapy
- •No negative second-look surgery
- •Secondary cytoreductive surgery for recurrent disease ≥ 6 months after completion of first-line chemotherapy
- •No greater than 1 cm residual disease at the completion of laparoscopy or laparotomy AND no diffuse carcinomatosis
- •Disease must be confined to the peritoneal cavity
- •Retroperitoneal disease ≤ 1 cm at the completion of prior surgery allowed
- •Not a candidate for a higher priority GOG protocol
- •No tumors of low malignant potential
- •PATIENT CHARACTERISTICS:
- •GOG performance status 0-2
- •Absolute neutrophil count ≥ 1,500/mm³
- •Platelet count ≥ 100,000/mm³
- •Creatinine ≤ 1.5 times upper limit of normal (ULN)
- •Bilirubin ≤ 1.5 times ULN
- •SGOT ≤ 2.5 times ULN
- •Alkaline phosphatase ≤ 2.5 times ULN
- •Neuropathy (sensory and motor) ≤ grade 1
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •No active infection requiring antibiotics
- •No other invasive malignancies within the past 5 years except nonmelanoma skin cancer
- •No extensive intra-abdominal adhesions
- •PRIOR CONCURRENT THERAPY:
- •See Disease Characteristics
- •Recovered from prior surgery or chemotherapy
- •No prior intraperitoneal therapy
- •No prior gemcitabine hydrochloride
- •No more than 1 prior regimen (including consolidation chemotherapy) for ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer
- •No radiotherapy to > 25% of marrow-bearing areas
- •No prior abdominal-pelvic radiotherapy
- •No prior cancer treatment that would preclude study therapy
- •No other prior therapy directed at the malignant tumor, including biological agents (unless this was part of front-line therapy), immunologic agents, vaccines, second-line chemotherapy, or hormonal therapy
- •Concurrent hormone replacement therapy allowed
- •No concurrent amifostine or other protective reagents
排除标准
- 未提供
结局指标
主要结局
Relative risk of progression-free survival
Frequency and severity of observed adverse effects by CTCAE version 3.0
次要结局
- Relative risk of survival
研究者
相似试验
已完成
2 期
Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerLung CancerNCT00326599Alliance for Clinical Trials in Oncology101
Unknown
2 期
Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal CancerHead and Neck CancerNCT00690872National Cancer Centre, Singapore35
已完成
2 期
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or CholangiocarcinomaExtrahepatic Bile Duct CancerGallbladder CancerNCT00033540SWOG Cancer Research Network57
已完成
2 期
Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the GallbladderExtrahepatic Bile Duct CancerGallbladder CancerNCT00084942Roswell Park Cancer Institute
撤回
2 期
Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerLung CancerNCT00951444Alliance for Clinical Trials in Oncology